Clinic and Polyclinic of Dermatology, University of Münster, Münster, Germany.
J Eur Acad Dermatol Venereol. 2011 Mar;25(3):251-8. doi: 10.1111/j.1468-3083.2010.03789.x.
Although emollients can be sufficient to manage mild atopic dermatitis (AD), acute flares resulting in moderate-to-severe symptoms require treatment with anti-inflammatory agents, such as topical corticosteroids (TCs) and topical calcineurin inhibitors (TCIs). This review examines the role of a member of the newest class of TCs, the fourth-generation compound methylprednisolone aceponate (MPA) in AD management, with reference to the chemical structure, pharmacokinetics, efficacy in AD, safety assessed in preclinical and clinical trials and dosing considerations. MPA has an optimized efficacy/safety profile with minimal local or systemic adverse effects. In addition, it offers the opportunity for once-daily dosing, which provides benefits in terms of patient compliance with treatment.
尽管保湿剂足以治疗轻度特应性皮炎（AD），但导致中度至重度症状的急性发作需要使用抗炎药物治疗，如局部皮质类固醇（TCs）和局部钙调神经磷酸酶抑制剂（TCIs）。本综述参考化学结构、药代动力学、AD 中的疗效、临床前和临床试验中的安全性评估以及剂量考虑因素，检查了最新一代 TCs 成员——第四代化合物甲泼尼龙醋酸酯（MPA）在 AD 管理中的作用。MPA 具有优化的疗效/安全性特征，局部或全身不良反应最小。此外，它还为每日一次给药提供了机会，这在患者治疗依从性方面带来了好处。
